Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.
A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease Experiencing End of Dose Wearing-Off
Sponsor: Acorda Therapeutics
Terminated
New Safety Information
A PHASE3 clinical study on Idiopathic Parkinson Disease, this trial is terminated or withdrawn. The trial is conducted by Acorda Therapeutics and has accumulated 11 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jun 2019 — Jan 2021 [monthly]
Terminated PHASE3
-
Jun 2018 — Jun 2019 [monthly]
Terminated PHASE3
▶ Show 6 earlier versions
-
Feb 2018 — Jun 2018 [monthly]
Terminated PHASE3
Status: Active Not Recruiting → Terminated
-
Dec 2017 — Feb 2018 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Oct 2017 — Dec 2017 [monthly]
Recruiting PHASE3
-
Sep 2017 — Oct 2017 [monthly]
Recruiting PHASE3
-
Aug 2017 — Sep 2017 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Feb 2017 — Aug 2017 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Acorda Therapeutics
- Biotie Therapies Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Asheville, United States , Atlantis, United States , Aventura, United States , Bloomfield Hills, United States , Boca Raton, United States , Charlottesville, United States , Des Moines, United States , Glasgow, United Kingdom , Golden Valley, United States , Honolulu, United States and 22 more locations